The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-coated devices used to treat peripheral artery disease (PAD) following its...
Stents Peripheral
Peripheral stents are used to open narrow and hardening arteries that supply blood to the legs and feet.
-
-
April 15, 2019 – Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System.
-
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
-
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent publication that suggests a possible increased risk of death at two years and...
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
August 28, 2019 — The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the...
News | Peripheral Artery Disease (PAD) | August 01, 2019
August 1, 2019 — Less-invasive procedures to open severely clogged...
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack...
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.
Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.
Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since...
News | Peripheral Artery Disease (PAD) | January 17, 2019
January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter...
Technology | Stents Peripheral | October 05, 2018
October 5, 2018 — Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent...
News | Peripheral Artery Disease (PAD) | May 15, 2018
May 15, 2018 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to...
News | Stents Peripheral | April 27, 2018
April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million. This financing is...
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.
Feature | Cath Lab | September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical...
News | Stents Peripheral | July 26, 2017
July 26, 2017 — Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the...
News | Peripheral Artery Disease (PAD) | July 17, 2017
July 17, 2017 — LimFlow SA announced enrollment of the first patient in the U.S....
News | Stents Peripheral | July 14, 2017
July 14, 2017 — Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an...
